ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic ... I think their current market cap seems like it's not fully pricing in its ...

ARS Pharmaceuticals (NASDAQ:SPRY) has signed a four-year agreement with ALK-Abelló A/S to co-promote neffy, its epinephrine nasal spray for Type I allergic reactions, to up to 9,000 pediatricians.

ARS Pharmaceuticals faces FDA rejection of its epinephrine nasal spray, neffy ... Management disclosed that R&D expenses were at a manageable $7.3M, a figure that suggests focused investment ...

Five Below And Other Big Stocks Moving Higher On Thursday Avi Kapoor FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment FDA approves ARS Pharma's Neffy ...

ARS Pharmaceuticals (SPRY) presents a compelling investment opportunity following the recent FDA approval of Neffy, its epinephrine nasal spray designed to disrupt the $1 billion annual EpiPen market.

An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...

On Friday, the FDA approved ARS Pharmaceuticals Inc’s (NASDAQ:SPRY) neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life ...